• 1. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 2. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 3. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 4. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 5. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Isocoumarans Phthalides
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Isocoumarans Isobenzofuranones Phthalides

Recent Advances in Mycophenolate Mofetil N-Oxide (EP Impurity G) Research: Key Findings and Implications

Mycophenolate Mofetil N-Oxide (EP Impurity G), with the CAS number 224052-51-1, is a critical impurity in the production and quality control of mycophenolate mofetil (MMF), a widely used immunosuppressive drug. Recent studies have focused on understanding its formation, stability, and potential impact on drug efficacy and safety. This research brief synthesizes the latest findings to provide a comprehensive overview of current knowledge and future directions.

A 2023 study published in the Journal of Pharmaceutical and Biomedical Analysis investigated the degradation pathways of MMF under various stress conditions, identifying EP Impurity G as a primary oxidative byproduct. The research utilized high-performance liquid chromatography (HPLC) and mass spectrometry (MS) to characterize the impurity, confirming its structure and proposing mechanisms for its formation. These findings are crucial for optimizing manufacturing processes to minimize impurity levels.

Another significant development comes from a collaborative effort between academic and industry researchers, who developed a novel synthetic route for EP Impurity G to serve as a reference standard. This work, detailed in a 2024 Organic Process Research & Development article, highlights the importance of reliable analytical standards in ensuring drug quality. The synthetic approach involved a selective oxidation of MMF using environmentally friendly catalysts, demonstrating advancements in green chemistry applications.

Recent regulatory updates from the European Pharmacopoeia have tightened the acceptable limits for EP Impurity G in MMF formulations, reflecting growing concerns about its potential biological activity. A 2023 toxicological assessment published in Chemical Research in Toxicology suggested that while EP Impurity G exhibits lower immunosuppressive activity compared to MMF, its long-term effects warrant further investigation. This has prompted pharmaceutical companies to invest in more sensitive detection methods and purification technologies.

Looking ahead, researchers are exploring the potential of computational chemistry to predict and control the formation of EP Impurity G during drug synthesis. Early results from molecular dynamics simulations, presented at the 2024 American Chemical Society meeting, show promise in identifying critical reaction parameters that influence impurity generation. Such approaches could revolutionize quality control in pharmaceutical manufacturing.

The collective progress in understanding Mycophenolate Mofetil N-Oxide (EP Impurity G) underscores the pharmaceutical industry's commitment to drug safety and quality. As analytical techniques become more sophisticated and regulatory standards more stringent, continued research in this area will be essential for maintaining the therapeutic efficacy of mycophenolate mofetil while minimizing potential risks associated with its impurities.

• 128794-94-5(Mycophenolate mofetil)
• 115007-34-6(Mycophenolate mofetil)
• 1322681-37-7(O-Methyl Mycophenolate Mofetil (EP Impurity D))
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)